Decorin inhibits the proliferation of HepG2 cells by elevating the expression of transforming growth factor-β receptor II.

The aim of the present study was to investigate the effects of decorin (DCN) on the proliferation of human hepatoma HepG2 cells and the involvement of transforming growth factor-β (TGF-β) signaling pathway. A vector containing DCN was transfected into HepG2 cells with the use of Lipofectamine 2000. Cell proliferation was assessed with an MTT assay, and western blot analysis was used to detect the protein expression of TGF-β receptor I (TGF-βRI), phosphorylated TGF-βRI, p15 and TGF-βRII. In addition, small interfering RNA (siRNA) silencing was performed to knock down the target gene. The results indicated that, compared with the control group, cell proliferation was significantly decreased in HepG2 cells transfected with DCN. In addition, DCN transfection significantly increased the phosphorylation level of TGF-βRI in HepG2 cells. The expression of the downstream factor p15 was also significantly elevated in the DCN-transfected HepG2 cells. Furthermore, DCN transfection significantly elevated the expression level of TGF-βRII in HepG2 cells. By contrast, the silencing of TGF-βRII significantly decreased the phosphorylation of TGF-βRI in DCN-transfected HepG2 cells. In addition, TGF-βRII silencing abolished the effects of DCN on the proliferation of HepG2 cells. In conclusion, DCN elevated the expression level of TGF-βRII, increased the phosphorylation level of TGF-βRI, enhanced the expression of p15, and finally inhibited the proliferation of HepG2 cells. These findings may contribute to the understanding of the role of DCN in the pathogenesis of hepatic carcinoma and assist in the disease treatment.